1McHutchison JG,Cheung R,Shiffman ML,et al.A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C [Abstract] [J].Hepatology,2001,34(Suppl ):329A.
2Brillanti S,Levantesi F,Masi L,et al.Triple antiviral therapy as a new option for patients withinterferon nonresponsive chronic hepatitis C[J].Hepatology,2000,32:630.
3Craxi A,Lo Iacono O.Amantadine for chronic hepatitis C:a magic bullet or yet another dead duck [J].J Hepatol,2001,35:527.
4Whitney M,Stack JH,Darke PL,et al.A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity [J].J Biomol Screening,2002,7:149.
5Ingallinella P,Fattori D,Altamura S,et al.Prime site binding inhibitors of a serine protease:NS3/4A of hepatitis C virus [J].Biochemistry,2002,41:5483.
6Fischmann TO,Weber PC.Peptidic inhibitors of the hepatitisC virus serine protease within non-structural protein 3 [J] .Curr Pharm Des,2002,8:2533.
7Narjes H,Yong CL,Steinmann G.Tolerability and pharmaco kinetics of BILN 2061,a novel HCV serine protease inhibitor,after oral single doses of 5 to 2 400 mg in healthy male subjects [J].Hepatology,2002,36 (Suppl.4,Pt.2):800
8Ingallinella P,Fattori D,Altamura S,et al.Prime site binding inhibitors of a serine protease:NS3/4A of hepatitis C virus [J].Biochemistry,2002,41:5483.
9Beaulieu PL,Llinas-Brunet M.Therapies for hepatitis C infection:targeting the non-structural proteins of HCV [J].Curr Med Chem,2002,1:163.
10Sommadossi JP,Lacolla P.Methods and compositions for treating hepatitis C virus [P].Int Patent Appl,WO 01/190121,2001,Idenix Pharmaceuticals.
